Sunday, April 17, 2016 11:55:37 PM
Abstract Number: 39
Presentation Title: UDP-N-acetylglucosamine as a regulator of cancer cell signaling and microenvironment
Presentation Time: Sunday, Apr 17, 2016, 1:00 PM - 5:00 PM
http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=eb59f5a2-3d2a-4ee5-9ed0-5c468da0a3a8&cKey=0a5a52c8-5cd8-44b5-aedb-85374b02a61e&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267
Abstract Number: 1217
Presentation Title: Preclinical evaluation of a next-generation, EGFR targeting ADC that promotes regression in KRAS or BRAF mutant tumors
Presentation Time: Monday, Apr 18, 2016, 8:00 AM -12:00 PM
http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=43ef76fe-c845-4b4b-8531-601f2b1c2c32&cKey=bb5dcf16-e379-432f-a72c-191183729d7b&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267
Abstract Number: 4886
Presentation Title: PEGylated recombinant hyaluronidase PH20 (PEGPH20) enhances checkpoint inhibitor efficacy in syngeneic mouse models of cancer
Presentation Time: Wednesday, Apr 20, 2016, 7:30 AM -11:00 AM
http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=7e29eea8-2919-415b-8225-9605d44075b1&cKey=fd03fab2-169d-48f5-a484-8e4def634287&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267
Abstract Number: 283
Presentation Title: PEGylated recombinant hyaluronidase PH20 (PEGPH20) enhances pemetrexed antitumor efficacy in a human nonsquamous NSCLC xenograft model
Presentation Time: Sunday, Apr 17, 2016, 1:00 PM - 5:00 PM
http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=8f12fb61-c4bc-4343-8b71-06552cd95a69&cKey=51f803a0-0b10-492d-9163-b3d7c0b42fef&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267
Abstract Number: 2463
Presentation Title: PEGPH20 increases the anticancer activity of standard chemotherapy combinations, vincristine (VIN) and D actinomycin (DACT), in a Wilms’ xenograft model
Presentation Time: Monday, Apr 18, 2016, 1:00 PM - 5:00 PM
http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=48925246-b6f3-45e7-a603-b6cdb4e0287d&cKey=11e33203-49a2-4419-95c5-6baa624f1c56&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267
Abstract Number: CT097
Presentation Title: A first-in-human phase I dose escalation study of the OX40 agonist MOXR0916 in patients with refractory solid tumors
Presentation Time: Tuesday, Apr 19, 2016, 10:58 AM -11:16 AM
Location: Room 391, Morial Convention Center
Webcast Status: Webcast Available
(notation here that slides are being witheld)
http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=b01a929a-449c-4fd7-89e5-7dc10238925f&cKey=39e0a216-850a-43fc-ab54-0727214f8117&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267
Recent HALO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/18/2024 10:49:57 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/18/2024 08:01:16 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/17/2024 08:03:48 PM
- Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis • PR Newswire (US) • 09/13/2024 05:30:00 PM
- Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer • PR Newswire (US) • 09/13/2024 12:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/12/2024 09:56:59 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/12/2024 08:12:07 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/11/2024 08:05:49 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/10/2024 08:16:18 PM
- Halozyme to Present at Upcoming Investor Conferences • PR Newswire (US) • 08/28/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/27/2024 11:49:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/21/2024 10:03:29 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/21/2024 08:11:18 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/20/2024 08:16:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/15/2024 08:59:35 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/15/2024 08:31:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:57:27 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/14/2024 08:08:38 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/13/2024 08:19:53 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 08:07:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 08:03:09 PM
- HALOZYME REPORTS SECOND QUARTER 2024 FINANCIAL AND OPERATING RESULTS • PR Newswire (US) • 08/06/2024 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/24/2024 09:48:14 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/24/2024 08:05:48 PM
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM